1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. California >
  6. Scopus BioPharma Acquires Olimmune

M&A Deal Summary

Scopus BioPharma Acquires Olimmune

On June 30, 2021, Scopus BioPharma acquired life science company Olimmune

Acquisition Highlights
  • This is Scopus BioPharma’s 1st transaction in the Life Science sector.
  • This is Scopus BioPharma’s 1st transaction in the United States.
  • This is Scopus BioPharma’s 1st transaction in California.

M&A Deal Summary
Date 2021-06-30
Target Olimmune
Sector Life Science
Buyer(s) Scopus BioPharma
Deal Type Add-on Acquisition

Target

Olimmune

Los Angeles, California, United States
Olimmune is an immunotherapy company, that develops oligonucleotide therapeutics to treat cancer and other diseases by regulating the immune system. Olimmune was founded in 2019 and is based in Los Angeles, California.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Scopus BioPharma

New York, New York, United States
Category Company
Founded 2017
Sector Life Science
Employees13
Revenue 12M USD (2022)
DESCRIPTION

Scopus BioPharma is a biopharmaceutical company developing transformational therapeutics targeting serious diseases with significant unmet medical needs. To achieve its mission, the company seeks to capitalize on ground-breaking scientific and medical discoveries at some of the world’s foremost academic and research institutions. Scopus BioPharma was formed in 2017 and is based in New York City.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
State: California M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2021 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal